Covid-19 Research

Case Report

Ginkgo biloba Extract Containing Plasmalogen May Improve Long COVID and Brain Fog: A Case Report

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Case Report
Subject Medicine Group
OCLC JBRES Record
Satoshi Kawakami*, Yoshimu Tanaka, Tsutomu Sato, Takaharu Ide, Masaaki Usui, Shigehisa Iida, Taro Shirakawa and Yoshitaka Fukuzawa
Issue: Volume3-Issue10
Pages: 1271-1275
Received: 2022-10-21
Accepted: 2022-10-27
Published: 2022-10-28

Abstract

Other than pneumonia, Long COVID is currently cited as a problem with COVID-19. Among them, brain fog is a particular problem. Brain fog, as the name suggests, refers to a state in which the brain is foggy, and it is thought that there is a communication abnormality in the central nervous system, including fatigue. It has been pointed out that this may be caused by a cytokine storm, and since it lowers QOL (Quality of Life), countermeasures are urgently needed. In this study, we used plasmalogen containing Ginkgo biloba extract and found improvement in patients complaining of brain fog. As a result, we were able to confirm a case of excellent efficacy, which we report here.

FullText HTML FullText PDF DOI: 10.37871/jbres1589 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2022 Kawakami S, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Kawakami S, Tanaka Y, Sato T, Ide T, Usui M, Iida S, Shirakawa T, Fukuzawa Y. Ginkgo biloba Extract Containing Plasmalogen May Improve Long COVID and Brain Fog: A Case Report. 2022 Oct 28; 3(10): 1271-1275. doi: 10.37871/jbres1589, Article ID: JBRES1589, Available at: https://www.jelsciences.com/articles/jbres1589.pdf

Subject area(s)

Public Health

References

  1. Sahoo P, Dey J, Mahapatra SR, Ghosh A, Jaiswal A, Padhi S, Prabhuswamimath SC, Misra N, Suar M. Nanotechnology and COVID-19 Convergence: Toward New Planetary Health Interventions Against the Pandemic. OMICS. 2022 Sep;26(9):473-488. doi: 10.1089/omi.2022.0072. Epub 2022 Aug 30. PMID: 36040392.
  2. Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Biofactors. 2021 Mar;47(2):232-241. doi: 10.1002/biof.1726. Epub 2021 Apr 12. PMID: 33847020; PMCID: PMC8250989.
  3. World Health Organization, Coronavirus disease (COVID-19): Post COVID-19 condition. 2021.
  4. Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Biofactors. 2021 Mar;47(2):232-241. doi: 10.1002/biof.1726. Epub 2021 Apr 12. PMID: 33847020; PMCID: PMC8250989.
  5. Carod-Artal FJ. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. Rev Neurol. 2021 Jun 1;72(11):384-396. English, Spanish. doi: 10.33588/rn.7211.2021230. PMID: 34042167.
  6. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021 Oct;53(10):737-754. doi: 10.1080/23744235.2021.1924397. Epub 2021 May 22. PMID: 34024217; PMCID: PMC8146298.
  7. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021 Oct;53(10):737-754. doi: 10.1080/23744235.2021.1924397. Epub 2021 May 22. PMID: 34024217; PMCID: PMC8146298.
  8. Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, Rizk D, Rozanski G, Breyman E, Nasr L, Kellner C, Herrera JE, Putrino D. Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life, and Participation. Am J Phys Med Rehabil. 2022 Jan 1;101(1):48-52. doi: 10.1097/PHM.0000000000001910. PMID: 34686631; PMCID: PMC8667685.
  9. Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol. 2020 Jun 23;11:1518. doi: 10.3389/fimmu.2020.01518. PMID: 32655582; PMCID: PMC7324760.
  10. Toldo S, Bussani R, Nuzzi V, Bonaventura A, Mauro AG, Cannatà A, Pillappa R, Sinagra G, Nana-Sinkam P, Sime P, Abbate A. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res. 2021 Jan;70(1):7-10. doi: 10.1007/s00011-020-01413-2. Epub 2020 Oct 20. PMID: 33079210; PMCID: PMC7572246.
  11. Robinson-Agramonte MA, Gonçalves CA, Noris-García E, Préndes Rivero N, Brigida AL, Schultz S, Siniscalco D, García García RJ. Impact of SARS-CoV-2 on neuropsychiatric disorders. World J Psychiatry. 2021 Jul 19;11(7):347-354. doi: 10.5498/wjp.v11.i7.347. PMID: 34327127; PMCID: PMC8311516.
  12. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13. PMID: 32167747; PMCID: PMC7094171.
  13. Pereira A. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front Neurol. 2020 Apr 17;11:308. doi: 10.3389/fneur.2020.00308. PMID: 32362868; PMCID: PMC7182030.
  14. Ortelli P, Ferrazzoli D, Sebastianelli L, Maestri R, Dezi S, Spampinato D, Saltuari L, Alibardi A, Engl M, Kofler M, Quartarone A, Koch G, Oliviero A, Versace V. Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID-19. Eur J Neurol. 2022 Jun;29(6):1652-1662. doi: 10.1111/ene.15278. Epub 2022 Feb 24. PMID: 35138693; PMCID: PMC9111319.
  15. Sandler CX, Wyller VBB, Moss-Morris R, Buchwald D, Crawley E, Hautvast J, Katz BZ, Knoop H, Little P, Taylor R, Wensaas KA, Lloyd AR. Long COVID and Post-infective Fatigue Syndrome: A Review. Open Forum Infect Dis. 2021 Sep 9;8(10):ofab440. doi: 10.1093/ofid/ofab440. PMID: 34631916; PMCID: PMC8496765.
  16. Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Mol Neurobiol. 2021 Mar;58(3):1017-1023. doi: 10.1007/s12035-020-02177-w. Epub 2020 Oct 19. PMID: 33078369; PMCID: PMC7571527.
  17. Stanciu GD, Luca A, Rusu RN, Bild V, Beschea Chiriac SI, Solcan C, Bild W, Ababei DC. Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement. Biomolecules. 2019 Dec 26;10(1):40. doi: 10.3390/biom10010040. PMID: 31888102; PMCID: PMC7022522.
  18. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, Mullally WJ, Pilgrim DM. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022 Mar;91(3):367-379. doi: 10.1002/ana.26286. Epub 2022 Jan 18. PMID: 34952975; PMCID: PMC9011495.
  19. Wirth KJ, Scheibenbogen C, Paul F. An attempt to explain the neurological symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J Transl Med. 2021 Nov 22;19(1):471. doi: 10.1186/s12967-021-03143-3. Erratum in: J Transl Med. 2022 Jan 11;20(1):25. PMID: 34809664; PMCID: PMC8607226.
  20. Diamond BJ, Bailey MR. Ginkgo biloba: indications, mechanisms, and safety. Psychiatr Clin North Am. 2013 Mar;36(1):73-83. doi: 10.1016/j.psc.2012.12.006. PMID: 23538078.
  21. Udagawa J, Hino K. Plasmalogen in the brain: Effects on cognitive functions and behaviors attributable to its properties. Brain Res Bull. 2022 Oct 1;188:197-202. doi: 10.1016/j.brainresbull.2022.08.008. Epub 2022 Aug 12. PMID: 35970332.
  22. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001 May;77(4):1168-80. doi: 10.1046/j.1471-4159.2001.00332.x. PMID: 11359882.
  23. Grimm MOW, Michaelson DM, Hartmann T. Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. J Lipid Res. 2017 Nov;58(11):2083-2101. doi: 10.1194/jlr.R076331. Epub 2017 May 20. PMID: 28528321; PMCID: PMC5665674.
  24. Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019 Jul;16(3):666-674. doi: 10.1007/s13311-019-00767-8. PMID: 31376068; PMCID: PMC6694352.
  25. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. 2000 May;81(5):668-78. doi: 10.1016/s0003-9993(00)90052-2. PMID: 10807109.
  26. Jarrott B, Head R, Pringle KG, Lumbers ER, Martin JH. "LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol Res Perspect. 2022 Feb;10(1):e00911. doi: 10.1002/prp2.911. PMID: 35029046; PMCID: PMC8929332.
  27. EGb 761: ginkgo biloba extract, Ginkor. Drugs R D. 2003;4(3):188-93. doi: 10.2165/00126839-200304030-00009. PMID: 12757407.
  28. Wells R, Paterson F, Bacchi S, Page A, Baumert M, Lau DH. Brain fog in postural tachycardia syndrome: An objective cerebral blood flow and neurocognitive analysis. J Arrhythm. 2020 Mar 3;36(3):549-552. doi: 10.1002/joa3.12325. PMID: 32528589; PMCID: PMC7280003.
  29. Gauthier CJ, Lefort M, Mekary S, Desjardins-Crépeau L, Skimminge A, Iversen P, Madjar C, Desjardins M, Lesage F, Garde E, Frouin F, Bherer L, Hoge RD. Hearts and minds: linking vascular rigidity and aerobic fitness with cognitive aging. Neurobiol Aging. 2015 Jan;36(1):304-14. doi: 10.1016/j.neurobiolaging.2014.08.018. Epub 2014 Aug 20. PMID: 25308963.
  30. Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. 2012 Sep;1822(9):1442-52. doi: 10.1016/j.bbadis.2012.05.008. Epub 2012 May 22. PMID: 22627108.
  31. Farooqui, A. A. (2001). “Plasmalogens: Workhorse lipids of membranes in normal and injured neurons and glia”. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry 7 (3): 232–245. doi:10.1177/107385840100700308. PMID 11499402.
  32. DeVries GH, Zetusky WJ, Zmachinski C, Calabrese VP. Lipid composition of axolemma-enriched fractions from human brains. J Lipid Res. 1981 Feb;22(2):208-16. PMID: 7240954.
  33. Mosconi TM, Rice FL, Song MJ. Sensory innervation in the inner conical body of the vibrissal follicle-sinus complex of the rat. J Comp Neurol. 1993 Feb 8;328(2):232-51. doi: 10.1002/cne.903280206. PMID: 8423242.
  34. Peters A. The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol. 2002 Sep-Nov;31(8-9):581-93. doi: 10.1023/a:1025731309829. PMID: 14501200.
  35. Brosche T, Platt D. The biological significance of plasmalogens in defense against oxidative damage. Exp Gerontol. 1998 Aug;33(5):363-9. doi: 10.1016/s0531-5565(98)00014-x. PMID: 9762517.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership